Understanding the Options Activity Surrounding Ultragenyx Pharmaceutical
In recent market movements, financial heavyweights have shown a clear bearish sentiment toward Ultragenyx Pharmaceutical. A detailed analysis of the options history for Ultragenyx Pharmaceutical (RARE) highlights 10 significant trades that reflect this trend.
Trader Sentiments on Ultragenyx Pharmaceutical
Our examination indicates that 30% of traders are leaning towards a bullish outlook, while an overwhelming 60% display bearish tendencies. Among the trades observed, 6 were puts, representing a total value of $276,249, alongside 4 calls valued at $290,790.
Projected Price Range Analysis
Based on the volume and open interest linked to these options contracts, it seems that investors have been eyeing a price range between $22.50 and $40.00 for Ultragenyx Pharmaceutical over the past three months. This range reflects the pricing aspirations of larger investors, often referred to as whales.
Insights into Volume and Open Interest
Scrutinizing the volume and open interest surrounding these trades provides vital insights. Understanding these metrics is essential for evaluating liquidity and the interest levels at specific strike prices for Ultragenyx Pharmaceutical. Below is a summary showcasing the trends in volume and open interest across key transactions within a strike price range of $22.50 to $40.00 from the past month.
Analysis of Recent Options Activity
In the past 30 days, notable trends have emerged regarding the options activity for Ultragenyx Pharmaceutical. Here are some of the key findings:
Key Options Activity
Some of the most significant options identified include:
Highlights from the Recent Trades
- **RARE**: CALL TRADE with a bullish sentiment and an expiration date of 12/19/25, transacted at a price of $2.10 for a total volume of 1,000 contracts.
- **RARE**: CALL SWEEP signaling bearish sentiment, set for expiration on 12/19/25, with a trading price of $4.80 and no volume recorded.
- **RARE**: PUT SWEEP expected on 02/20/26, priced at $3.50 representing a total trade volume of 250 contracts.
- **RARE**: PUT TRADE with bearish expectations due 07/18/25, closing at $4.70 and involving a trade volume of 652 contracts.
- **RARE**: A secondary PUT TRADE comparable to the above, with identical parameters but a total trade price of $4.70 across 452 contracts.
Company Overview: Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing novel solutions for the treatment of rare and ultra-rare genetic diseases. Their portfolio includes significant products like Crysvita for treating X-linked hypophosphatemia and Mepsevii for Mucopolysaccharidosis VII.
Current Market Position of Ultragenyx
As of now, Ultragenyx maintains a trading volume of 9,702,498, with the stock currently valued at $33.21, reflecting a decline of 19.86%. The relative strength index (RSI) indicates that the stock may be oversold, providing potential opportunities for strategic entries. Additionally, upcoming earnings are expected to be announced in just a few weeks.
Expert Opinions on Ultragenyx Pharmaceutical
In the past month, analysts have shared their insights about Ultragenyx, establishing an average target price around $64.50 for the stock. One analyst from Wells Fargo maintains an Overweight rating, eyeing a price of $65, while another from Guggenheim has adjusted forecasts to a Buy rating with a target price of $64.
Implication of Options Activity
Options trading can introduce risks, necessitating careful management strategies. Traders adept in this field mitigate risks by staying educated on market movements, employing varied indicators, and adjusting their portfolios to navigate changing conditions.
Frequently Asked Questions
What has been the overall sentiment for Ultragenyx Pharmaceutical options?
The majority of traders are currently adopting a bearish stance, with 60% showing this tendency while only 30% are bullish.
What is the projected price range for Ultragenyx Pharmaceutical?
Investors are targeting a price range between $22.50 to $40.00 for Ultragenyx Pharmaceutical over the upcoming months.
Who are the notable analysts covering Ultragenyx Pharmaceutical?
Analysts from Wells Fargo and Guggenheim have shared insights, with recommendations ranging from Overweight to Buy.
What is the current stock performance for RARE?
Ultragenyx's stock (RARE) is trading at $33.21, reflecting a significant decline of 19.86% recently.
How can one stay updated on options activity for Ultragenyx Pharmaceutical?
Investors can monitor real-time updates through financial tools and platforms dedicated to options data for timely trading opportunities.
